Pfizer plans price hikes on 41 drugs despite pressure from Trump, Democrats

Published



Pfizer will raise the prices of 41 drugs in January, amid escalating Trump administration efforts to lower prescription drug prices and months after President Trump’s intervention forced the largest U.S. drugmaker to postpone planned cost increases.

The hikes, first reported by the Wall Street Journal, will affect 5 percent of the company’s total drug portfolio and will be offset with higher rebates and discounts, Pfizer said in a statement. The Trump administration is expected to try to overhaul the drug rebate program, an effort departing CEO Ian Read previously told investors would advance in 2018.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.